{"schema_version":"secwatch.filing_event.v1","accession":"0001213900-22-046528","form_type":"8-K","ticker":"INM","cik":"0001728328","company_name":"InMed Pharmaceuticals Inc.","filed_at":"2022-08-11T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.833772+00:00","generated_at":"2026-06-24T00:57:00.637359+00:00","sec_items":["5.02","7.01","9.01"],"event_type":"leadership","sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"confidence":"high","headline":"InMed appoints Nicole Lemerond to board; Adam Cutler resigns","bullets":["Adam Cutler resigned from board effective Aug 8, 2022; no disagreement with the company.","Nicole Lemerond appointed to board effective Aug 8, 2022; fills vacancy on Audit and Governance Committees.","Ms. Lemerond has 25+ years in investment management, private equity, healthcare finance; CFA charterholder.","Standard director compensation: $45,000 annual retainer plus options for 14,000 common shares."],"urls":{"canonical":"https://secwatch.observer/filing/0001213900-22-046528","json":"https://secwatch.observer/filing/0001213900-22-046528.json","markdown":"https://secwatch.observer/filing/0001213900-22-046528.md","text":"https://secwatch.observer/filing/0001213900-22-046528.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022046528/0001213900-22-046528-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022046528/ea164185-8k_inmedphar.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T00:57:00.637359+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"861c7d33ce","claim":"Nicole Lemerond was appointed as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"the Board appointed Nicole Lemerond as a director of the Board to fill the vacancy created by Mr. Cutler’s resignation, effective as of August 8, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022046528/0001213900-22-046528-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"appointed"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"},{"claim_id":"a582802d26","claim":"Adam Cutler resigned as Director at InMed Pharmaceuticals Inc..","evidence_excerpt":"Adam Cutler resigned from the Board of Directors (the “Board”) (including from the Nominating & Corporate Governance Committee and the Audit Committee) of the Company, effective as of August 8, 2022.","evidence_source":"SEC 8-K Item 5.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/1728328/000121390022046528/0001213900-22-046528-index.htm","confidence":0.95,"family_label":"Executive change","details":[{"label":"Action","value":"resigned"},{"label":"Role","value":"Director"}],"fact_type":"executive_change"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}